WITH STANDARDS – UNLOCK THE POWER OF DATA



#### Clinical Data Standards, Governance Process: How Far We've Come and Where We're Going

Presented by: Donna Sattler, Associate Director, Clinical Data Standards, Bristol-Myers Squibb Sharon Hartpence, Associate Director, Clinical Data Standards, Bristol-Myers Squibb



### **Meet the Speakers**

#### **Donna Sattler**

Title: Associate Director, Clinical Data Standards

#### **Organization:** Bristol-Myers Squibb

I've worked in various Data Management and Programming roles for over 25 years. I made a career change 20 years ago which brought me into the world of clinical research and data standards. I am deeply motivated by helping to influence, educate, and communicate Data Standards, through process improvements and best practices across the enterprise.

#### Sharon Hartpence

#### Title: Associate Director, Clinical Data Standards

**Organization:** Bristol-Myers Squibb

As an RN, BSN, MBA who has worked in Pharmaceutical Research and Development for over 25 .As an eDC data collection specialist; I've developed clinical trial processes to streamline efficiencies for end-users. I continue to increase my knowledge of CDISC implementation best practices by engaging in opportunities with CDISC collaboration initiatives



## **Disclaimer and Disclosures**

- The views and opinions expressed in this presentation are those of the author(s) and do not necessarily reflect the official policy or position of CDISC.
- Additionally, the presenters are expressing their opinions on how the industry has utilized data standards over the years and not representing the processes of BMS but rather best practices for all end users of data standards.




## Agenda

- 1. Data Standards, History...
- 2. Standards Governance and Guardrails
- 3. What's next...
- 4. Best Practices & Key Takeaways







If collection is not appropriate for your study, you can request a change through a change request governance process

6

cdisc

## Remember When....

•

# ... Data Standards consisted of whatever study you last worked on ...in any disease area and use that as your starting point...

- ✓ You were given a table mock-up with raw data annotations
- ✓ When there was a mismatch from QC you relied on quick fixes in the SAS code like: if then do; logic for updating any value in the final dataset to pass compliance. Each study had its own unique mapping spec which was always updated to match the code to the final output. But that was it...
- ✓ Standards SDTM Mapping specs were not the norm; we borrowed mapping templates from previous studies....by running a comparison between study metadata to then obtain a % close match.





#### Make this table.....

Study Population: Safety	rand, RA	EBO rand. RA	Home yand. RI	\$ 12 MG	
Characteristic	Placebo (N=xx)	6 mg (N=xx)	12 mg (N=xx)	Total (N=xx)	
Mean head hist HHSTDTC SD Range (Min, Max)	жж.ж жж.ж (жж, жж)	** **.* **.* (**,**)	×× PHILAU PHARMA PROTOCOL NO. A	xx CEUTICAL, INC.	DATASET : HEADHIST.xpt
mset of Current Headache Episode (weeks) Maan SD Range (Min, Max)	жж жж.ж жж.ж (жк, жк)	жж жж. ж (жж. жж)	Investigator No.	Screening No.	Patient Initials Patient No.
tumber of Headaches n (3) head hast. HHTOT $xx (x.x)$ 2-5 xx (x.x) 55 xx (x.x)		xx (x.x) xx (x.x) xx (x.x)	HEADACHE HISTORY		
Family History of Headaches n (4) Yes No head hist. AHFAMCD	xx (x,x) xx (x,x) xx (x,x) xx (x,x) xx (x,x) xx (x,x)		Headache Onset Date of Onset of th	ne patient's headaches	hhstdtc   Date of Onset:   m m d d y y y y
			Current Headach Date of Onset of th headaches	es he CURRENT episode of	hhcstdtc Date of Onset:
Proc Sort data = vaw. headhist date headhist; marge vand hh; by invo patid;	cat = hh cat = rank			Headaches ent headache, what is the tot les the patient has had since	
merge vand hh;			□ 1	hhtot	
by invo patid;			□ 2-5		
sum)			5+		hhfamcd
		Does this patient h	nave a family history of heada	iches? 0 🗌 No 1 🗌 Yes	

cdisc

## ...You first heard of CDISC?

- ✓ 20 years ago there was no understanding of the sustainability of CDISC standards, there was still a lot of hesitancy to put the long-term investment into standardizing
- ✓ Tables and listings were company standards based on raw data metadata. SDTM was still a concept.
- ✓ USUBJID was the first standards variable I ever created.
- ✓ No SDTM mapping specs, no SDTM Annotated CRFs









# Governance Guardrails...


cdisc

- Many different functions are a part of the content creation in addition to when changes can and should be made. No one function "owns" the standards. The same holds true for Governance. It is a collaborative effort to maintain standards and limit the changes to existing forms once they are considered universal or global.
- Many groups have a stake in the reusability of the standards; therefore, they too get to impart their function's needs for what should not change or what must change to align to business needs.

## **Governance Team Charter Example**

The primary responsibility of the Clinical Data Standards Governance Organization is to implement effective governance in the development and maintenance of clinical data standards.

This governance organization will enable standards implementation, ensure the necessary resources to implement clinical data standards, and create processes that support and facilitate the use of consistent evolving global clinical data standards.





## Change Request Example



# **STANDARDS CHANGE REQUEST SCENARIO**

The Clinical Team identified a need for modification of an existing eCRF (indication-specific change)

#### **Request:**

Add new options to the CMINDC code list (#1) plus Other, Specify field. (#2)

#### Rationale:

The teal vould like to know the specific type of Protate Cancer each systemic therapy was used for. Currently the CMINDC dictionary only includes **Prostate Cancer**. The team would like to add additional types of prostate cancer as well as an **Other** option and a question to specify the other type of prostate cancer.



Form: Prior and Concomitant Medications	
For what indication was the medication/therapy taken?	for choices PROSTATE CANCER
Category for Medication	HORMONAL ANTI-CANCER THERAPIES FOR DISEASE
Indication list	UNDER STUDY ANTI-MYELOMA THERAPIES
For field #1:	BISPHOSPHONATE
= Deplized prostate canour	HORMONAL ANTI-CANCER
- lo calized prostate cancer - castration-naive prostate cancer	THERAPIES FOR DISEASE NOT
- non-metastatic hormone sensitive prostate cancer	UNDER STUDY
- non-metaslatic castration-resistant prostate cancer	CARDIOVASCULAR
metastatic hormone sensitive prostate cancer	
- metastatic castration-resistant prostate cancer	INDICATION
	DIABETES
-other	DISEASE UNDER STUDY
A we we all all and some inter	GENERAL
hadfuld for if other, specify	GROWTH FACTORS

# **STANDARDS CHANGE REQUEST SCENARIO**

The Clinical Team identified a need for modification of an existing eCRF (indication-specific change)

#### **Request:**


Add new options to the CMINDC code list (#1) plus Other, Specify field. (#2)

#### Rationale:

The teal are of the like to know the specific type of Prostate Cancer each systemic therapy was used for. Currently the CMINDC dictionary only includes **Prostate Cancer**. The team would like to add additional types of prostate cancer as well as an **Other** option and a question to specify the other type of prostate cancer.



Form: Prior and Concomitant Medications	
For what indication was the medication/therapy taken? SEE UST BELD W f	PROSTATE CANCER
Category for Medication	HORMONAL ANTI-CANCER THERAPIES FOR DISEASE
Indication list	UNDER STUDY ANTI-MYELOMA THERAPIES
for field #1:	BISPHOSPHONATE
- localized prostate cancer	HORMONAL ANTI-CANCER
- localized prostate cancer - castration-naive prostate cancer	THERAPIES FOR DISEASE NOT
- non-metastatic normone sensitive prostate cancer	UNDER STUDY CARDIOVASCULAR
-non-metaslatic castration-resistant prostate cancer	INDICATION
metastatic hormone sensitive prostate cancer	CEREBROVASCULAR
- metastatic castration-registant prostate cancer	INDICATION
-Other	DIABETES
	DISEASE UNDER STUDY
hadfuld for if other, specify	GENERAL
	GROWTH FACTORS



# What's Next...

## New ways of managing collection and reporting Standards....

New Ways	Pros	Cons
MDRs	Traceability, the promise of being one source of truth for all company Standardization, ie: when one concept/object changes, it's relationships are also updated.	Unexpected glitches Requires a lot of training and process workarounds for accommodating tool
External Data Collection Processes	Standardization SMEs are necessary to manage vendor expectations while keeping true to internal BMS standards. (i.e tablet, CGM, watch, etc)	Requires additional resources to manage external data requirements
eCOA/ePRO Processes	One data specification for all eCOA/ePRO data collection	Requires additional resources to manage external data requirements
Decentralized Study Data Considerations	Faster start-up, cleaner data, fewer resources	Requires systems to talk with one another




## Consider these Best Practices & Key Takeaways....

### **Best Practices....**

- Ensure Alignment for E2E Impact Assessment by training all users on the standards metadata
- Create Change Request Checklists and use a Change Request Template when changes need to be requested
- Do not assume what is being asked for is already in the protocol or that the requester is fully aware of all the possibilities in existing standards
- Front-load discussions and impact analysis prior to implementing a new change request.







## Thank You!

donna.sattler@bms.com

sharon.hartpence@bms.com

